Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Shares of Hansoh Pharmaceutical Group rose 4.3% to HK$35.76, their highest level since September 9, after the company said its phase III clinical trial of HS-10374 in treatment of moderate-to-severe plaque psoriasis met co-primary and multiple secondary endpoints. The drug demonstrated a favourable safety and tolerabil
Hansoh Pharmaceutical Group Company Limited said its drug HS-10374 met co-primary endpoints in a Phase III trial for plaque psoriasis.
Hansoh Pharma reported positive results from a pivotal Phase 3 trial for its psoriasis drug HS-10374 in adults with moderate-to-severe plaque psoriasis. The study met its primary endpoints, showing clear clinical improvement compared to placebo and supporting a favorable benefit-risk profile within the TYK2 class. The